ALLMedicine™ Atrial Flutter Center

Nov 18th, 2022 - We aimed to compare cryoballoon pulmonary vein isolation (PVI) with standard radiofrequency cavotricuspid isthmus (CTI) ablation as first-line treatment for typical atrial flutter (AFL). Cryoballoon Pulmonary Vein Isolation as First-Line Treatment...

Nov 12th, 2022 - Pulmonary vein isolation (PVI) is widely accepted as an effective and safe treatment for symptomatic atrial fibrillation (AF). However, data on sex-related differences and associations with clinical outcome and safety of PVI with cryoballoon ablat...

Nov 11th, 2022 - Current estimates suggest that a patent foramen ovale (PFO) may exist in up to 25% of the general population and is a potential risk factor for embolic, ischemic stroke. PFO closure complications include bleeding, need for procedure-related surgic...

Nov 11th, 2022 - Use of a novel magnetic sensor enabled optical contact force ablation catheter has been established to be safe and effective for treatment of symptomatic drug-refractory paroxysmal atrial fibrillation (AF) but has yet to be demonstrated in the per...

Nov 10th, 2022 - Although many studies have supported the efficacy of transplacental treatment for fetal supraventricular tachyarrhythmias, the long-term neurodevelopmental outcome after antenatal antiarrhythmic treatment is not well understood. The aim of this st...

Dec 12th, 2020 - 2020 Update to the 2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures.|2020|Hei...

Feb 19th, 2011 - The stroke rate in atrial fibrillation is 4.5% per year, with death or permanent disability in over half. The risk of stroke varies from under 1% to over 20% per year, related to the risk factors of congestive heart failure, hypertension, age, dia...

Feb 20th, 2008 - ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the...

Oct 4th, 2022 - The purpose of this study is to measure the long term effectiveness，clinical benefit, and safety outcomes of catheter ablation with STSF and AI for paroxysmal atrial fibrillation (PAF) subjects up to 12-month follow-up. Subject:Up to 150 PAF subj...

Sep 30th, 2022 - Catheter ablation of the cavotricuspid isthmus (CTI) is an effective and safe procedure in patients with atrial flutter (AFL) with excellent long-term results in preventing AFL recurrences. However, new-onset atrial fibrillation (AF) commonly deve...

Sep 26th, 2022 - The goal of the GENETIC-AF trial is to demonstrate the superiority of pharmacogenetically targeted bucindolol compared to metoprolol for the prevention of symptomatic atrial fibrillation or atrial flutter in a genotype-defined population with hear...

Sep 14th, 2022 - Investigators will prospectively enroll 200 adult participants referred to the Johns Hopkins Hospital for catheter ablation of atrial fibrillation (AF). Investigators will first enroll participants with paroxysmal AF (n=100) to complete sensitivit...

Sep 7th, 2022 - Prospective, non-randomized, post market clinical evaluation of the VISITAG SURPOINT™ Module with External Processing Unit (EPU) when used with STSF catheter and ST catheter compared to an historical control performance goal. A maximum of 330 subj...

Nov 4th, 2022 - Please note that the text below is not a full transcript and has not been copyedited. For more insight and commentary on these stories, subscribe to the This Week in Cardiology podcast on Apple Podcasts, Spotify, or your preferred podcast provider...

Oct 27th, 2022 - The probability of spontaneous conversion to sinus rhythm (SVC) was increased with the intravenous administration of magnesium and potassium in patients with nonpermanent atrial fibrillation presenting to the ER, a new registry study shows. Compar...

Oct 24th, 2022 - The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of zanubrutinib (Brukinsa) for use in adult patients with marginal zone lymphoma (MZL) who have received at least 1 prior anti–CD20-...

Oct 14th, 2022 - The ability of an Apple Watch to detect atrial fibrillation (AF) is significantly affected by underlying ECG abnormalities such as sinus node dysfunction, atrioventricular (AV) block, or intraventricular conduction delay (IVCD), a single-center st...

Sep 12th, 2022 - The combination of orelabrutinib (ICP-022) and rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) elicited a favorable overall response rate (ORR) and progression-free survival (PFS) rate in patients with prev...